Walleye Capital’s Evolent Health EVH Stock Holding History

Walleye Capital’s Portfolio EVH Stock Details EVH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$97K	Buy	+17,900	New	+$68.6K	﹤0.01%	3914
2026 Q1	–	Sell	-12,800	Closed	-$51.2K	–	4563
2025 Q4	$51.2K	Sell	12,800 -9,800	-43%	-$54.5K	﹤0.01%	4072
2025 Q3	$191K	Buy	+22,600	New	+$219K	﹤0.01%	3345
2025 Q2	–	Sell	-6,500	Closed	-$61.6K	–	4644
2025 Q1	$61.6K	Sell	6,500 -10,000	-61%	-$101K	﹤0.01%	3785
2024 Q4	$186K	Sell	16,500 -24,800	-60%	-$436K	﹤0.01%	3814
2024 Q3	$1.17M	Buy	+41,300	New	+$1.06M	﹤0.01%	2489
2023 Q2	–	Sell	-5,400	Closed	-$175K	–	4471
2023 Q1	$175K	Buy	+5,400	New	+$171K	﹤0.01%	2565
2019 Q2	–	Sell	-23,200	Closed	-$292K	–	1823
2019 Q1	$292K	Buy	+23,200	New	+$367K	0.05%	613

Other funds holding EVH

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

CCM

Cadian Capital Management New York $1.32B AUM 4.19% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Rubicon Founders Nashville, Tennessee $196M AUM 53.12% 1-Year Est. Return

Engaged Capital Newport Beach, California $327M AUM 22.96% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Walleye Capital's EVH Position: Q2 2026 in Review

Walleye Capital increased its Evolent Health (EVH) stake by 522% in Q2 2026, buying an estimated $2.72M and bringing the position to 845,787 shares worth $4.58M. The position accounts for 0.02% of the portfolio, ranked #880.

Walleye Capital first reported a position in EVH in Q2 2019 and has held it in 12 quarters since. The position peaked at $7.29M in Q2 2025. 198 funds tracked by Wall St. Rank hold EVH as of Q2 2026.

Walleye Capital held 845,787 shares of Evolent Health worth $4.58M as of Q2 2026.
Walleye Capital bought 709,839 Evolent Health shares in Q2 2026, an estimated $2.72M.
Evolent Health made up 0.02% of Walleye Capital's portfolio in Q2 2026, its #880 holding.
Walleye Capital first reported a position in Evolent Health in Q2 2019 and has held it in 12 quarters since.
Walleye Capital's Evolent Health position peaked at $7.29M in Q2 2025.
198 funds tracked by Wall St. Rank held Evolent Health as of Q2 2026.

Based on Walleye Capital's 13F filing for Q2 2026, filed 3 Aug 2026.